Cannabis legalization is already happening, regardless of what any politician says…
Former Vice President Joe Biden is at it again.
He’s chirping about reigning in cannabis legalization.
And like most other pandering statements from politicians, I’m here to tell you, they are a distraction.
Late last year, he called marijuana a gateway drug. But in a recent interview with the Editorial Board of the New York Times, he backpedaled. Now he’s calling for more research while supporting decriminalization.
Regardless of what he says, don’t put too much weight on Biden’s or any other politician’s comments – especially in an election year.
Sure, what gets said can move cannabis stocks around in the short term. But as cannabis stocks rally or fall based on a dropped statement here or a talking point there, it’s important to not get caught up in the noise.
Ultimately, cannabis legalization is proceeding, regardless of what any politician says. None are bold enough to make a strong stand against it. And anything short of all-out war is mere posturing.
“Fools rush in where angels fear to tread.”
And only a fool would jump in front of the cannabis legalization train…
Looking Beyond Politics
This time, in his interview with the New York Times, Joe Biden argues that marijuana needs to be researched.
No one can possibly argue against that.
But that research is happening anyway. And there are massive opportunities to profit by investing in those companies funding the most research into the effects of THC, CBD, and the 100-plus other cannabinoids produced by the marijuana and hemp plants.
It’s something I’ve written about before – and you’ll hear it from me again.
So, rather than get caught up in politically calculated statements, I want to give you a look at four companies doing great things to advance the science of cannabis.
Pay Attention to These 4 Companies
I spend all day every day looking at companies like the ones I’m about to tell you about.
In fact, my team has put together a database of over 200 cannabis stocks. We call it NICILytics, and it’s loaded with reports, market stats, and our ratings of these companies.
It’s an invaluable resource that holds everything you need to get ahead of other investors. I invite you to find out how you can gain full access to this powerful tool here.
Now, the first company I want to tell you about is GW Pharmaceuticals PLC (Nasdaq: GWPH).
GW Pharmaceuticals ran clinical trials on CBD as a treatment for two rare forms of epilepsy and received approval from the Food and Drug Administration (FDA). The drug is sold under the brand name Epidiolex.
To pass the trials, the company paid to have the drug’s safety tested on tens of people, the drug’s efficacy tested on hundreds of patients, and ultimately administered to thousands of patients in controlled studies. These studies required significant coordination between doctors and the research labs conducting the trials.
Now, Epidiolex got approved more quickly than usual because the diseases it was being used to treat were very rare – but this was very intensive research nonetheless.
Another company, InMed Pharmaceuticals (OTC: IMLFF), is testing another cannabinoid – cannabinol (CBN) – to treat Epidermolysis Bullosa. It is also testing this same molecule as a treatment for glaucoma in pre-clinical, non-human studies.
And there is a lot of research underway that doesn’t involve the FDA or clinical trials.
Yet another company, Tilray Inc. (Nasdaq: TLRY), is supporting clinical studies being conducted at the McGill University Health Centre in Quebec. Its CBD and THC capsules will be used to study how well medical cannabis can boost the immune systems of people living with human immunodeficiency virus (HIV).
As one last example, Aurora Cannabis Inc. (NYSE: ACB) has partnered with the Ultimate Fighting Championship (UFC) to research the impact that CBD can have on athletes’ performance and ability to recover.
The research is being led by Jason Dyck, Ph.D. at the University of Alberta, and Duncan French, Ph.D., at the UFC Performance Institute.
These examples just barely scratch the surface of everything that’s going on. Information is also being collected from doctors prescribing cannabis to medical cannabis patients – providing rich fields of data from which further insights and discoveries can be gleaned.
Cannabis research is well underway alongside the expansion of an individual’s right to consume it.
Federal legalization in the U.S. could be just weeks away. See how you could set yourself up for potential profits of 626% or more when that happens.
An Invaluable Lesson
So the next time a politician weighs into the cannabis debate, keep this in mind: legalizing cannabis doesn’t require a politician’s approval.
Citizens can tell politicians what the laws will be through ballot measures. And that’s exactly what’s happening across the country.
Citizens want access to inexpensive and effective medicine. They are tired of the disproportionate impact that vain drug laws have on disadvantaged communities. And they want the freedom to choose.
Marijuana legalization strikes me as one of the few, genuine, bottom-up, power-to-the-people movements to have occurred in the United States. That’s what makes it both inevitable – and so very profitable.
Till next time,
Don Yocham, CFA
Executive Director, National Institute for Cannabis Investors
12 responses to “These 4 Companies Are Ushering in a New Era for Cannabis”
February 06 2020